image: A new study finds that a clinically approved cholesterol-lowering drug may be less toxic to the liver than previously thought. This material relates to a paper that appeared in the Jan. 27, 2016 issue of Science Translational Medicine, published by AAAS. The paper, by G. Reyes-Soffer at Columbia University College of Physicians and Surgeons in New York, NY, and colleagues was titled, "Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans." view more
Credit: Val Altounian / <i>Science Translational Medicine</i>